Listen: Vaccine riches, patent waivers, & a gene therapy for aging

What does $45 billion buy you these days? Is clinical trial tourism a business? And will no one think of the patents?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, Moderna and Pfizer are poised to make billions of dollars from their Covid-19 vaccines this year, and we discuss what that massive infusion of cash portends for both companies. Next, Thomas Bollyky of the Council on Foreign Relations joins us to explain what the U.S.’s support for waiving Covid-19 vaccine patents means — and doesn’t mean — for the global vaccination effort. Finally, STAT’s Megan Molteni calls in to share the story of a little-known biotech company recruiting patients to Mexico with the promise of an anti-aging gene therapy in an unregulated clinical trial.

For more on what we cover, here’s more on Pfizer and Moderna; here’s the patent waiver news; here’s the gene therapy story; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.


Be sure to sign up on Apple PodcastsStitcherGoogle Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].

Source: STAT